Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer

Niclosamide has preclinical activity against a wide range of cancers. In prostate cancer, it inhibits androgen receptor variant 7 and synergizes with abiraterone. The approved niclosamide formulation has poor oral bioavailability. The primary objective of this phase Ib trial was to identify a maximu...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Sci Rep
Autors principals: Parikh, Mamta, Liu, Chengfei, Wu, Chun-Yi, Evans, Christopher P., Dall’Era, Marc, Robles, Daniel, Lara, Primo N., Agarwal, Neeraj, Gao, Allen C., Pan, Chong-Xian
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7973745/
https://ncbi.nlm.nih.gov/pubmed/33737681
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-85969-x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars